BMS Paid for Celgene With a $9 Promise That Expired at Zero 36 Days Late

When Bristol Myers Squibb bought Celgene in 2019, it didn't just hand over stock and cash. It handed over a promise, sliced into roughly 715 million tradable pieces. Each Celgene share converted into one BMS share, fifty dollars, and one contingent value right — a slip of paper that would pay $9 if, and only if, three specific cancer and MS drugs cleared the FDA by their deadlines.² Do the math on the promise and it comes to about $6.4 billion.⁷ Two of the three drugs made their dates. The third made it too — just thirty-six days late.³ And the whole $6.4 billion vanished.

The story that spread afterward is that BMS slow-walked the FDA to dodge a $6.4 billion bill. The record so far says something less cinematic and more instructive: a smart contract clause, written to protect the buyer, worked exactly as written — and a near-miss triggered a total forfeiture the courts have not found anyone rigged.

The clause that made a near-miss worth nothing: the contract had no partial credit — three approvals by deadline, or zero

The mechanism is the whole story, so read it slowly. The CVR did not pay per drug. It did not pay a sliding scale for two-out-of-three. It paid $9 in full if all three milestone drugs — liso-cel, ozanimod, and ide-cel — were approved by their set FDA deadlines, and it paid zero otherwise. Even a one-day-late approval on any single drug voided the entire payout.² Ozanimod cleared in March 2020. Ide-cel cleared as Abecma by its March 31, 2021 deadline.⁷ But liso-cel — later marketed as Breyanzi — had a December 31, 2020 deadline, and its FDA approval did not arrive until February 5, 2021.² By the terms of the CVR Agreement dated November 20, 2019, that one miss automatically terminated the whole instrument on January 1, 2021. The CVRs became ineligible for payment and stopped trading on the NYSE the next day.¹ Two hits and a five-week miss produced not a partial payout but a complete one — a complete zero.

The market saw it coming, priced in dollars: the CVR never 'was worth $9' — it was a live bet on approval odds

The lazy retelling says the CVR 'was worth $9' and then 'became worthless.' That misreads what the security was. It was a publicly traded option on a binary event, listed on the NYSE under its own ticker, and its price moved as the odds moved. It opened near $9 when the merger closed and the milestones still looked achievable. Then, through 2020, as two of the covered medicines ran into delays, the market marked it down hard — all the way to about $1.⁶ That price was not a valuation of the drugs. It was the crowd's running estimate of the probability that every deadline would be met. By late 2020 the market had already concluded the odds were poor, which is exactly why the January 1 termination surprised almost no one who was watching the tape. The $9 was never paid to anyone; it was a ceiling the security spent its whole life below.

Didn't BMS just stall the FDA to keep the money?: it's the obvious suspicion — and so far the courts have not sustained it

This is the fair, cynical objection, and it deserves a straight answer: BMS had $6.4 billion of reasons to want liso-cel to slip past its deadline, and the drug slipped past its deadline. Motive plus outcome looks damning. But motive is not proof, and when former shareholders sued, a federal judge — Jesse Furman in the Southern District of New York — dismissed the securities-fraud claim, finding no proof that BMS deliberately dragged its feet to avoid the payout; the delay traced to preapproval inspection problems at BMS and its manufacturing contractor Lonza.⁴ That is the honest counter to my own thesis: the question of intent is not settled in BMS's favor either. A separate breach-of-contract suit, brought in June 2021 by the CVR trustee, alleged BMS failed to use the 'diligent efforts' the agreement required, with damages to be set at trial — and BMS disputed it and moved to dismiss.⁵ So the record is genuinely unresolved on effort. What it does not support, as of now, is the confident claim that BMS engineered the miss. The most defensible reading is duller and more useful: the contract, not a conspiracy, did most of the destroying.

There is one final trap worth naming, because it's how casual retellings garble this story. The dead $9 milestone CVR is not the only thing called a 'Celgene CVR.' A separate, older, far smaller right — tied to Abraxane net sales — kept quietly paying out, distributing about fourteen cents per right in early 2021 even as the big one collapsed.⁸ Same word, two instruments, opposite fates. The lesson under all of it is the same one contract lawyers keep relearning and everyone else keeps forgetting: the number on the ticket is not the promise. The clause is the promise. The Celgene CVR said $9, traded near a dollar, and paid nothing — and the reason was never the drugs. It was thirty-six days, met by a sentence with no partial credit in it.